Preview

Кардиология

Расширенный поиск
Доступ открыт Открытый доступ  Доступ закрыт Доступ платный или только для Подписчиков

Клеточная терапия в комплексном лечении пациента с дилатационной кардиомиопатией. Клиническое наблюдение

https://doi.org/10.18087/cardio.2555

Полный текст:

Аннотация

Приведено 13-летнее клиническое наблюдение за пациентом с дилатационной кардиомиопатией. В 2005 г. больному с ХСН IV ФК по NYHA было выполнено интракоронарное введение аутологичной мононуклеарной фракции костного мозга с положительной динамикой клинического состояния (I ФК ХСН) и длительной ремиссией (10 лет). В 2015 г. из-за ухудшения течения заболевания выполнено повторное интракоронарное введение аутологичной мононуклеарной фракции костного мозга, которое состояло из двух последовательных введений с разницей между ними 9 месяцев. Отмечаются выраженная положительная динамика ФВ и размеров ЛЖ в течение 3 лет наблюдения, улучшение качества жизни пациента. Наблюдение за больным будет продолжено.

Об авторах

С. А. Белый
ФГБОУ ВО «ПСПбГМУ им. акад. И. П. Павлова» МЗ РФ
Россия

197022, Санкт-Петербург, ул. Л. Толстого, д. 6/8



В. И. Лукашенко
ФГБОУ ВО «ПСПбГМУ им. акад. И. П. Павлова» МЗ РФ
Россия

197022, Санкт-Петербург, ул. Л. Толстого, д. 6/8



В. В. Комок
ФГБОУ ВО «ПСПбГМУ им. акад. И. П. Павлова» МЗ РФ
Россия

197022, Санкт-Петербург, ул. Л. Толстого, д. 6/8



Г. Г. Хубулава
ФГБОУ ВО «ПСПбГМУ им. акад. И. П. Павлова» МЗ РФ
Россия

197022, Санкт-Петербург, ул. Л. Толстого, д. 6/8



Список литературы

1. Braunwald E. Cardiomyopathies: An Overview. Circulation Research. 2017;121(7):711–21. DOI: 10.1161/CIRCRESAHA.117.311812

2. Maron BJ. Contemporary Defnitions and Classifcation of the Cardiomyopathies: An American Heart Association Scientifc Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Commitee, Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups, and Council on Epidemiology and Prevention. Circulation. 2006;113(14):1807–16. DOI: 10.1161/CIRCULATIONAHA.106.174287

3. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Defnition and Classifcation of Cardiomyopathies. Circulation. 1996;93(5):841–2. DOI: 10.1161/01.CIR.93.5.841

4. McKenna WJ, Maron BJ, Tiene G. Classifcation, Epidemiology, and Global Burden of Cardiomyopathies. Circulation Research. 2017;121(7):722–30. DOI: 10.1161/CIRCRESAHA.117.309711

5. Merlo M, Stolfo D, Anzini M, Negri F, Pinamonti B, Barbati G et al. Persistent recovery of normal lef ventricular function and dimension in idiopathic dilated cardiomyopathy during long‐term follow‐up: does real healing exist? Journal of the American Heart Association. 2015;4(1):e001504. DOI: 10.1161/JAHA.114.000570

6. Moon J, Shim CY, Kim Y-J, Park S, Kang S-M, Chung N et al. Lef Atrial Volume as a Predictor of Lef Ventricular Functional Recovery in Patients with Dilated Cardiomyopathy and Absence of Delayed Enhancement in Cardiac Magnetic Resonance. Journal of Cardiac Failure. 2016;22(4):265–71. DOI: 10.1016/j.cardfail.2015.12.011

7. Matsumura Y, Hoshikawa-Nagai E, Kubo T, Yamasaki N, Kitaoka H, Takata J et al. Prediction of lef ventricular reverse remodeling afer therapy with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers and β blockers in patients with idiopathic dilated cardiomyopathy. Cardiovascular Ultrasound. 2015;13(1):14. DOI: 10.1186/s12947-015-0009-4

8. McNamara DM, Starling RC, Cooper LT, Boehmer JP, Mather PJ, Janosko KM et al. Clinical and Demographic Predictors of Outcomes in Recent Onset Dilated Cardiomyopathy. Journal of the American College of Cardiology. 2011;58(11):1112–8. DOI: 10.1016/j.jacc.2011.05.033

9. Di Lenarda A, Pinamonti B, Mestroni L, Salvi A, Sabbadini G, Gregori D et al. Te natural history of dilated cardiomyopathy: a review of the Heart Muscle Disease Registry of Trieste. Italian Heart Journal. Supplement: Ofcial Journal of the Italian Federation of Cardiology. 2004;5(4):253–66. PMID: 15346692

10. Merlo M, Caiffa T, Gobbo M, Adamo L, Sinagra G. Reverse remodeling in Dilated Cardiomyopathy: Insights and future perspectives. IJC Heart & Vasculature. 2018;18:52–7. DOI: 10.1016/j.ijcha.2018.02.005

11. Martin-Rendon E. Meta-Analyses of Human Cell-Based Cardiac Regeneration TerapiesResponse to Martin-Rendon: What Can Systematic Reviews Tell Us About Cell Terapies for Ischemic Heart Disease? Circulation Research. 2016;118(8):1264–72. DOI: 10.1161/CIRCRESAHA.115.307540

12. Fisher SA, Doree C, Mathur A, Martin-Rendon E. Meta-Analysis of Cell Terapy Trials for Patients with Heart Failure. Circulation Research. 2015;116(8):1361–77. DOI: 10.1161/CIRCRESAHA.116.304386

13. Fisher SA, Doree C, Mathur A, Taggart DP, Martin-Rendon E. Stem cell therapy for chronic ischaemic heart disease and congestive heart failure. Cochrane Database of Systematic Reviews. 2016, DOI: 10.1002/14651858.CD007888.pub3

14. Белый С. А., Комок В. В. Клеточная терапия хронической сердечной недостаточности – современное состояние проблемы. Кардиология. 2018;58(S4):46-54. DOI: 10.18087/cardio.2442

15. Caforio ALP, Pankuweit S, Arbustini E, Basso C, Gimeno-Blanes J, Felix SB et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. European Heart Journal. 2013;34(33):2636– 48. DOI: 10.1093/eurheartj/eht210

16. Krejci J, Mlejnek D, Sochorova D, Nemec P. Inflammatory Cardiomyopathy: A Current View on the Pathophysiology, Diagnosis, and Treatment. BioMed Research International. 2016;2016:4087632. DOI: 10.1155/2016/4087632

17. Sánchez-Trujillo L, Vázquez-Garza E, Castillo EC, García-Rivas G, Torre-Amione G. Role of Adaptive Immunity in the Development and Progression of Heart Failure: New Evidence. Archives of Medical Research. 2017;48(1):1–11. DOI: 10.1016/j.arcmed.2016.12.008

18. Ismahil MA, Hamid T, Bansal SS, Patel B, Kingery JR, Prabhu SD. Remodeling of the Mononuclear Phagocyte Network Underlies Chronic Inflammation and Disease Progression in Heart Failure: Critical Importance of the Cardiosplenic Axis. Circulation Research. 2014;114(2):266–82. DOI: 10.1161/CIRCRESAHA.113.301720

19. Van Linthout S, Tschöpe C. Inflammation – Cause or Consequence of Heart Failure or Both? Current Heart Failure Reports. 2017;14(4):251–65. DOI: 10.1007/s11897-017-0337-9

20. Rock KL, Lai J-J, Kono H. Innate and adaptive immune responses to cell death: Immunological reaction to cell death. Immunological Reviews. 2011;243(1):191–205. DOI: 10.1111/j.1600-065X.2011.01040.x

21. Bolli R. Repeated Cell Terapy: A Paradigm Shif Whose Time Has Come. Circulation Research. 2017;120(7):1072–4. DOI: 10.1161/CIRCRESAHA.117.310710

22. Tokita Y, Tang X–L, Li Q, Wysoczynski M, Hong KU, Nakamura S et al. Repeated Administrations of Cardiac Progenitor Cells Are Markedly More Effective Tan a Single Administration: A New Paradigm in Cell Terapy. Circulation Research. 2016;119(5):635– 51. DOI: 10.1161/CIRCRESAHA.116.308937

23. Guo Y, Wysoczynski M, Nong Y, Tomlin A, Zhu X, Gumpert AM et al. Repeated doses of cardiac mesenchymal cells are therapeutically superior to a single dose in mice with old myocardial infarction. Basic Research in Cardiology. 2017;112(2):18. DOI: 10.1007/s00395-017-0606-5

24. Tang X, Nakamura S, Li Q, Wysoczynski M, Gumpert AM, Wu W et al. Repeated Administrations of Cardiac Progenitor Cells Are Superior to a Single Administration of an Equivalent Cumulative Dose. Journal of the American Heart Association. 2018;7(4):pii: e007400. DOI: 10.1161/JAHA.117.007400

25. Wysoczynki M, Khan A, Bolli R. New Paradigms in Cell Terapy: Repeated Dosing, Intravenous Delivery, Immunomodulatory Actions, and New Cell Types. Circulation Research. 2018;123(2): 138–58. DOI: 10.1161/CIRCRESAHA.118.313251

26. Kubal C, Sheth K, Nadal-Ginard B, Galiñanes M. Bone marrow cells have a potent anti-ischemic effect against myocardial cell death in humans. Te Journal of Toracic and Cardiovascular Surgery. 2006;132(5):1112–8. DOI: 10.1016/j.jtcvs.2006.06.028

27. Duran JM, Makarewich CA, Sharp TE, Starosta T, Zhu F, Hoffman NE et al. Bone-Derived Stem Cells Repair the Heart Afer Myocardial Infarction Trough Transdifferentiation and Paracrine Signaling Mechanisms. Circulation Research. 2013;113(5):539– 52. DOI: 10.1161/CIRCRESAHA.113.301202

28. Hodgkinson CP, Bareja A, Gomez JA, Dzau VJ. Emerging Concepts in Paracrine Mechanisms in Regenerative Cardiovascular Medicine and Biology. Circulation Research. 2016;118(1):95–107. DOI: 10.1161/CIRCRESAHA.115.305373

29. Karantalis V, Balkan W, Schulman IH, Hatzistergos KE, Hare JM. Cell-based therapy for prevention and reversal of myocardial remodeling. American Journal of Physiology-Heart and Circulatory Physiology. 2012;303(3):H256–70. DOI: 10.1152/ajpheart.00221.2012

30. Alestalo K, Mietinen JA, Vuolteenaho O, Huikuri H, Lehenkari P. Bone Marrow Mononuclear Cell Transplantation Restores Inflammatory Balance of Cytokines afer ST Segment Elevation Myocardial Infarction. PLOS ONE. 2015;10(12): e0145094. DOI: 10.1371/journal.pone.0145094

31. Barile L, Cerisoli F, Frati G, Gaetani R, Chimenti I, Forte E et al. Bone marrow-derived cells can acquire cardiac stem cells properties in damaged heart. Journal of Cellular and Molecular Medicine. 2011;15(1):63–71. DOI: 10.1111/j.1582-4934.2009.00968.x

32. Yoon C-H, Koyanagi M, Iekushi K, Seeger F, Urbich C, Zeiher AM et al. Mechanism of Improved Cardiac Function Afer Bone Marrow Mononuclear Cell Terapy: Role of Cardiovascular Lineage Commitment. Circulation. 2010;121(18):2001–11. DOI: 10.1161/CIRCULATIONAHA.109.909291

33. Van den Akker F, Deddens JC, Doevendans PA, Sluijter JPG. Cardiac stem cell therapy to modulate inflammation upon myocardial infarction. Biochimica et Biophysica Acta (BBA) – General Subjects. 2013;1830(2):2449–58. DOI: 10.1016/j.bbagen.2012.08.026

34. Marguti I, Yamamoto GL, da Costa TB, Rizzo LV, de Moraes LV. Expansion of CD4+ CD25+ Foxp3+ T cells by bone marrowderived dendritic cells: In vitro Treg expansion by dendritic cells. Immunology. 2009;127(1):50–61. DOI: 10.1111/j.1365-2567.2008.02927.x

35. Chen B, Frangogiannis NG. Immune cells in repair of the infarcted myocardium. Microcirculation. 2017;24(1):e12305. DOI: 10.1111/micc.12305

36. Lu Y, Wang Y, Lin M, Zhou J, Wang Z, Jiang M et al. A systematic review of randomised controlled trials examining the therapeutic effects of adult bone marrow-derived stem cells for non-ischaemic dilated cardiomyopathy. Stem Cell Research & Terapy. 2016;7(1):186. DOI: 10.1186/s13287-016-0441-x

37. Jiao R, Liu Y, Yang W-J, Zhu X-Y, Li J, Tang Q-Z. Effects of stem cell therapy on dilated cardiomyopathy. Saudi Medical Journal. 2014;35(12):1463–8. PMID: 25491210

38. Marquis-Gravel G, Stevens L–M, Mansour S, Avram R, Noiseux N. Stem Cell Terapy for the Treatment of Nonischemic Cardiomyopathy: A Systematic Review of the Literature and Meta-analysis of Randomized Controlled Trials. Canadian Journal of Cardiology. 2014;30(11):1378–84. DOI: 10.1016/j.cjca.2014.03.026

39. Poglajen G, Zemljič G, Frljak S, Cerar A, Andročec V, Sever M et al. Stem Cell Terapy in Patients with Chronic Nonischemic Heart Failure. Stem Cells International. 2018;2018:6487812. DOI: 10.1155/2018/6487812


Для цитирования:


Белый С.А., Лукашенко В.И., Комок В.В., Хубулава Г.Г. Клеточная терапия в комплексном лечении пациента с дилатационной кардиомиопатией. Клиническое наблюдение. Кардиология. 2019;59(4S):59-64. https://doi.org/10.18087/cardio.2555

For citation:


Beliy S.A., Lukashenko V.I., Komok V.V., Khubulava G.G. Cell therapy in the multimodality treatment of a patient with dilated cardiomyopathy. A case report. Kardiologiia. 2019;59(4S):59-64. (In Russ.) https://doi.org/10.18087/cardio.2555

Просмотров: 109


ISSN 0022-9040 (Print)
ISSN 2412-5660 (Online)